News | May 25, 2026
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Lifts full-year outlook as obesity drug boom accelerates
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Subscribe To Our Newsletter & Stay Updated
